Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
At the ESCMID Global 2026, the Microbiology & Infection Diagnostics division of Bruker Corporation unveiled a major advancement in molecular diagnostics with the European launch of the MyGenius PRO. This next-generation platform is designed to address the growing need for faster, more efficient infectious disease testing, particularly in high-demand laboratory environments.
The MyGenius PRO system represents a fully automated, sample-to-answer (S2A) molecular diagnostics solution built on Polymerase Chain Reaction (PCR) technology. By integrating every step of the diagnostic workflow—from initial patient sample processing through to final result interpretation—the system significantly reduces manual intervention and streamlines laboratory operations. This automation is particularly valuable in modern clinical settings, where laboratories are under increasing pressure to deliver accurate results quickly while managing rising test volumes.
One of the defining features of MyGenius PRO is its high-throughput capability combined with operational flexibility. The platform allows for continuous loading of samples, reagents, and consumables, eliminating the need to wait for batch processing cycles to complete. Additionally, its random-access functionality enables laboratories to prioritize urgent samples without disrupting ongoing workflows. These features collectively enhance efficiency, reduce turnaround times, and support the timely delivery of diagnostic insights that are critical for patient care.
The system builds upon the success of Bruker’s existing BeGenius platform, which has been widely recognized for its adaptability across various assays and sample types. While BeGenius offers strong flexibility, MyGenius PRO takes a step further by delivering higher throughput and more comprehensive automation. This evolution reflects Bruker’s ongoing commitment to innovation in molecular diagnostics and its focus on meeting the evolving needs of clinical laboratories.
At launch, the MyGenius PRO platform will support a targeted menu of IVDR-compliant assays addressing key viral infections that are particularly relevant for immunocompromised patients. These include tests for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) using whole blood samples, as well as BK virus (BKV) detection from urine samples. These pathogens are of significant clinical concern in patients with weakened immune systems, such as transplant recipients, where early detection and monitoring are essential for effective disease management.
Looking ahead, Bruker has outlined an ambitious roadmap for expanding the assay menu throughout 2026. Planned additions include assays for Human Immunodeficiency Virus type 1 (HIV-1), Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human Herpesvirus 6 (HHV-6), along with support for additional sample matrices. This rapid expansion strategy is intended to broaden the clinical utility of the MyGenius PRO platform and position it as a comprehensive solution for infectious disease diagnostics.
The development of MyGenius PRO is the result of a strategic collaboration between ELITechGroup, a Bruker company specializing in molecular assays, and Hitachi High-Tech Corporation, known for its expertise in advanced automation and engineering. By combining their respective strengths, the partners have created a platform that integrates cutting-edge assay development with robust, scalable instrumentation.
As part of this collaboration, Hitachi High-Tech will introduce the system in the Japanese market under the name LABOSPECT GA-5. In Japan, the platform will be paired with Bruker’s molecular diagnostic assays tailored to meet local regulatory requirements, ensuring compliance while maintaining high performance standards. This dual-market strategy highlights the global potential of the MyGenius PRO platform and underscores the importance of regional partnerships in advancing diagnostic innovation.
The importance of high-throughput, automated diagnostic systems has been emphasized by experts in the field. Pierangelo Clerici, President of AMCLI, has noted that timely diagnosis is a cornerstone of effective microbiology and virology practice. Fully automated, sample-to-result solutions like MyGenius PRO can significantly improve turnaround times, enabling faster clinical decision-making and more effective infection monitoring. Moreover, such systems help laboratories optimize workflows and maintain compliance with evolving regulatory frameworks, including the European In Vitro Diagnostic Regulation (IVDR).
The introduction of MyGenius PRO marks a significant milestone in Bruker’s broader molecular diagnostics strategy. The company continues to expand its portfolio, which already includes platforms such as InGenius and BeGenius, alongside a growing menu of CE-IVD assays. Additionally, Bruker is advancing innovative technologies like LiquidArray, which enable advanced multiplexing and more cost-effective syndromic panel testing.
Together, these developments reflect a comprehensive approach to addressing the challenges of modern infectious disease diagnostics. By integrating automation, scalability, and assay innovation, Bruker aims to empower laboratories with tools that not only enhance operational efficiency but also improve patient outcomes. As the demand for rapid and reliable diagnostic solutions continues to grow, platforms like MyGenius PRO are poised to play a critical role in shaping the future of clinical microbiology.
In summary, the European launch of MyGenius PRO at ESCMID Global 2026 underscores Bruker’s commitment to advancing molecular diagnostics through innovation and collaboration. With its high-throughput capabilities, flexible workflow design, and expanding assay menu, the platform is well-positioned to meet the evolving needs of healthcare systems and contribute to more effective management of infectious diseases worldwide.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI.
Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
About Hitachi High-Tech
Hitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including manufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. Hitachi High-Tech also provide high value-added solutions in industrial fields such as mobility, environment and energy, etc.
Source Link:https://www.businesswire.com/
